

BIBLIOGRAFÍA ALGORITMO DM2 SEMG

1. American Diabetes Association. Glycemic targets: Standards of medical care in diabetes—2022. *Diabetes Care*. 2022;45(Suppl 1):S83–96. doi:10.2337/dc22-S007.
2. American Diabetes Association. Standards of care in diabetes—2024. *Diabetes Care*. 2024;47(Suppl 1):S1–18. doi:10.2337/dc24-S001.
3. American Diabetes Association. Standards of care in diabetes—2025. *Diabetes Care*. 2025;48(Suppl 1):S1–16. doi:10.2337/dc25-S001.
4. American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: Standards of care in diabetes—2025. *Diabetes Care*. 2025;48(Suppl 1):S239–51. doi:10.2337/dc25-S011.
5. American Diabetes Association Professional Practice Committee. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of care in diabetes—2025. *Diabetes Care*. 2025;48(Suppl 1):S86–127. doi:10.2337/dc25-S005.
6. American Diabetes Association Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of care in diabetes—2025. *Diabetes Care*. 2025;48(Suppl 1):S167–80. doi:10.2337/dc25-S008.
7. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. *N Engl J Med*. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394.
8. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383(23):2219–29. doi:10.1056/NEJMoa2025845.

BIBLIOGRAFÍA ALGORITMO DM2 SEMG

9. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med*. 2020;383(23):2219–29. doi:10.1056/NEJMoa2025845.
10. Benlloch S, Moncho F, Górriz JL. Esteatosis hepática metabólica y nefropatía diabética: Una llamada a la acción. *Nefrología*. 2023;44(Supl 1):1–8. doi:10.1016/j.nefro.2023.08.005.
11. Bover J, Segura de la Morena J, Goicoechea Diezhandino M, et al. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. *Nefrología (Madr)*. 2022;42(3):233–64.
12. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486.
13. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45:2753–86. doi:10.2337/dci22-0034.
14. De Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). *Diabetes Care*. 2022;45:3075–90. doi:10.2337/dci22-0027.
15. Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition therapy for adults with diabetes or prediabetes: A consensus report. *Diabetes Care*. 2019;42(5):731–54. doi:10.2337/dci19-0014.

BIBLIOGRAFÍA ALGORITMO DM2 SEMG

16. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*. 2020;383(15):1436–46. doi:10.1056/NEJMoa2025845.
17. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. *Lancet Diabetes Endocrinol*. 2022;10(11):774–85. doi:10.1016/S2213-8587(22)00243-1.
18. Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int*. 2024;105(4 Suppl):S117–314.
19. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int*. 2022;102(Suppl 5S):S1–127. doi:10.1016/j.kint.2022.06.008.
20. Kosiborod MN, Jhund PS, Docherty KF, Komajda M, Chopra VK, Atherton JJ, et al. Semaglutide in patients with heart failure with preserved ejection fraction and diabetes: the STEP-HFpEF DM trial. *N Engl J Med*. 2024;390(15):1383–96. doi:10.1056/NEJMoa2401304.
21. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J*. 2023;44(39):4043–4140. doi:10.1093/eurheartj/ehad567.
22. Martín-García R, et al. Intervenciones enfermeras orientadas a prevenir la fragilidad en personas mayores. *Nutr Clín Diet Hosp*. 2023;43(2):162–71. doi:10.12873/432martingarcia.

BIBLIOGRAFÍA ALGORITMO DM2 SEMG

23. Ministerio de Sanidad. Actualización del documento de consenso sobre prevención de la fragilidad en la persona mayor (2022). Madrid: Ministerio de Sanidad; 2022. Disponible en: https://www.sanidad.gob.es/areas/promocionPrevencion/envejecimientoSaludable/fragilidadCaidas/docs/ActualizacionDoc_FragilidadyCaidas_personamayor.pdf.
24. Nassif ME, Kosiborod MN, Jhund PS, Bakris GL, Vardeny O, Givertz MM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med*. 2024;391(21):1993–2008. doi:10.1056/NEJMoa2407356.
25. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondy N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377(7):644–57. doi:10.1056/NEJMoa1611925.
26. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med*. 2019;380(24):2295–306. doi:10.1056/NEJMoa1811744.
27. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive type 2 diabetes management algorithm – 2023 update. *Endocr Pract*. 2023;29(5):305–40. doi:10.1016/j.eprac.2023.02.001.
28. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis. *N Engl J Med*. 2025;392(21):2089–99. doi:10.1056/NEJMoa2413258.
29. Wilding JPH, van Gaal L, Leiter LA, Pi-Sunyer X, Blüher M, Mathieu C, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2023;389(14):1257–69. doi:10.1056/NEJMoa2307154.

BIBLIOGRAFÍA ALGORITMO DM2 SEMG

30. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380(4):347-57. doi:10.1056/NEJMoa1812389.
31. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*. 2019;393(10166):31-9. doi:10.1016/S0140-6736(18)32590-X.
32. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720.
33. Zugasti-Murillo A, Casas-Herrero A. Síndrome de fragilidad y estado nutricional: Valoración, prevención y tratamiento. *Nutr Hosp*. 2019;36(2):26-37. doi:10.20960/nh.02412.

ABORDAJE TERAPÉUTICO EN PACIENTES CON DM2

DIABETOSEMG 2025

COORDINADORES

- Carlos Miranda Fernández-Santos
- Isabel Egocheaga Cabello
- Teresa Benedito Pérez de Inestrosa
- Yasmín Drak Hernández

GRUPO DE TRABAJO

Coordinadora:

- María José Peña Mateo

Miembros:

- Sara del Amo Ramos
- Alonso Peinado Cano
- María Eva Sáez Torralba
- José M^a Tarradellas Banchs
- Verónica Zurdo de Pedro

⋮ *En representación del Grupo
de Trabajo en Cardiovascular
y Diabetes de la SEMG*

REVISOR EXTERNO

- Esteban Jódar Gimeno

1^a edición:
septiembre 2025